Cure Addiction Now Forum and Webinar
Thank you to all who joined us at the September 2024 Cure Addiction Now Forum and Webinar. Your participation helped make the event a success. Watch the full event footage below to relive the insights and panel discussions.
Forum Details
A discussion with the most prominent and leading scientists at the forefront of Substance Use Disorder (SUD) and mental health research was held. Our forum was a unique opportunity to learn about the latest advances to stop this devastating disease.
Panelists
Cecilia Bergeria, Ph.D., Johns Hopkins University School of Medicine
Sandra Comer, Ph.D., Columbia University Irving Medical Center
Nancy Davis, CAN Founder and President
Kelly E. Dunn, Ph.D., Johns Hopkins School of Medicine
Jennifer Ellis, Ph.D., Johns Hopkins School of Medicine
Cassandra D. Gipson-Reichardt, Ph.D., University of Kentucky
Christian Hendershot, Ph.D., Keck School of Medicine of USC
Andrew A Herring, MD, PI Bridge Center, Public Health Institute
Adam Kaplin, M.D, Ph.D., Miralogx Inc.
James J. Mahoney, III, Ph.D., West Virginia University Medicine
Christopher Toombs, Ph.D., DABT, Proniras Corporation
Agenda
I. Welcome: Nancy Davis, Founder and President of CAN
II. Moderator and Introduction of Panel: Kurt Rasmussen, Ph.D., CSO Delix Therapeutics and Scientific Advisory Board, Chair for Cure Addiction Now
III. Living with substance use disorder: Lisa Vidal, Guest Panelist and Advocate
IV. Topics
- Need for Innovation in the Treatment of Substance Use Disorders: Kelly E. Dunn, Ph.D., Johns Hopkins University School of Medicine
- Focused Ultrasound Neuromodulation as an Adjunctive Treatment Strategy for SUD: James J. Mahoney, III, Ph.D., Rockefeller Neuroscience Institute, WVU Medicine
- Ketamine in the ED as a Way to Help Treat Precipitated and/or Unmanaged Opioid Withdrawal: Andrew A Herring, MD, PI Bridge Center, Public Health Institute
- Semaglutide (Ozempic) as a Potential Treatment for Alcohol Use Disorder: Christian Hendershot, Ph.D., Keck School of Medicine of USC
- Tezampanel: A New Medication for Opiate Withdrawal: Christopher Toombs, Ph.D., DABT, co-Founder and Chief Scientific Officer for Proniras Corporation
- Cimetidine as a Potential Therapeutic to Reduce Fentanyl Withdrawal Severity: Cassandra D. Gipson-Reichardt, Ph.D., University of Kentucky
- Scientists are Creating More Paths to Success for Individuals with Substance Use Disorders: Cecilia Bergeria, Ph.D., Johns Hopkins University School of Medicine
- Vaccines and Monoclonal Antibodies as Treatments for Opioid Use Disorder and Opioid Overdose: Sandra Comer, Ph.D., Columbia University Irving Medical Center
- Evaluating Suvorexant for Persons Who use Both Opioids and Cocaine - Feasibility and Lessons Learned: Jennifer Ellis, Ph.D., Johns Hopkins School of Medicine
- Public Health Policy and SUD: Adam Kaplin, M.D, Ph.D., CSO MyMD Pharmaceuticals
IV. Lightning Round: Answers to Submitted Questions
V. Conclusion and Thank You by Nancy Davis
2024 Fall Forum Gallery
To view the full gallery, click here.